3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
2
Conditions
Fallopian Tube Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Interventions
Paclitaxel
7
pembrolizumab
6
olaparib
5
Carboplatin
4
Bevacizumab
4
tisotumab vedotin
2
niraparib
2
mirvetuximab soravtansine
2
durvalumab
2
defactinib
2
Topotecan
2
Taxes
2
Saline Solution
2
Immunoglobulin G
2
Disulfides
2
Cisplatin
2
ulixertinib
1
trastuzumab biosimilar HLX02
1
trametinib
1
sodium thiosulfate
1
sapanisertib
1
sacituzumab govitecan
1
rucaparib
1
relatlimab
1
relacorilant
1
pertuzumab
1
palbociclib
1
osimertinib
1
omipalisib
1
liposomal doxorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has announcements
×
mirvetuximab soravtansine
×
Gynecologic
×
Clear all
NCT04209855
2025-08-27
MIRASOL
AbbVie
Phase 3
Completed
453 enrolled
18 charts
1 FDA
NCT04296890
2024-08-07
SORAYA
ImmunoGen, Inc.
Phase 3
Completed
106 enrolled
14 charts
1 FDA